Tyler Miller, MD, PhD

About

Motivated by a deep-seated desire to make a positive impact on the world, Dr. Tyler Miller has spent the last 16 years focused on cancer research. His current work at University Hospitals and Case Western Reserve University School of Medicine is dedicated to advancing immunotherapy treatments for brain tumors. As a physician-scientist, he combines his clinical expertise in molecular pathology with scientific expertise in cancer biology, genomics, and technology development to try to create innovative therapeutic strategies that significantly enhance the effectiveness of treatments.

Dr. Miller’s scientific journey began in 2006 at The Ohio State University, where his undergraduate research identified some of the first microRNAs linked to cancer treatment resistance. This work was followed by significant discoveries during his medical and graduate studies at CWRU and Cleveland Clinic, where he developed novel in vivo assays for glioblastoma target discovery and discovered a number of new potential therapeutic targets for brain tumors.

In 2018, Dr. Miller moved to Massachusetts General Hospital for a Clinical Pathology residency and to continue his research. After witnessing the limitations of targeted molecular therapies in clinical settings due to tumor heterogeneity, Dr. Miller pivoted his focus towards immunotherapy, convinced that engaging the immune system is the key to overcoming these challenges. During his residency and postdoctoral tenure at MGH and Dana Farber Cancer Institute, he advanced single-cell RNA sequencing technologies and our understanding of immunosuppressive myeloid cells in brain tumors. His current research leverages cutting-edge genomic technologies and novel ex vivo organoid models to further understand and manipulate myeloid cell states within tumors, aiming to transform these cells from tumor enablers to potent anti-cancer agents.

Beyond his scientific endeavors, Dr. Miller is dedicated to broadening access to advanced medical treatments through his Advisory role with Care Access. Here, he champions efforts to expand clinical trial access to underrepresented communities, striving to enhance diversity in clinical research and reduce health disparities. This work is part of his broader vision to ensure that cutting-edge therapies are within reach for all patients, regardless of their background or location.

As Dr. Miller continues to build his laboratory and research program at University Hospitals and Case Western, he remains committed to mentoring the next generation of scientists and clinicians, fostering an environment of growth, inclusivity, and innovation. His ultimate goal is to see his research translate into effective treatments that offer new hope to patients with brain tumors, thereby creating a significant and enduring impact for these patients and their families.

Outside the laboratory, Dr. Miller enjoys boating on Lake Erie and partaking in the vibrant food, arts, and sports scenes of Cleveland with his wife of 14 years and their two young kids.

Visit Ty Miller Lab